List of bibliographic references
Number of relevant bibliographic references: 8.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 8 | Female |
| 8 | Humans |
| 6 | Ovarian Neoplasms (genetics) |
| 4 | Mutation |
| 3 | Adult |
| 3 | Middle Aged |
| 3 | Neoplasms, Glandular and Epithelial (genetics) |
| 3 | Ovarian Neoplasms (drug therapy) |
| 3 | Young Adult |
| 2 | Adolescent |
| 2 | Aged |
| 2 | Aged, 80 and over |
| 2 | Antineoplastic Agents (therapeutic use) |
| 2 | BRCA1 Protein (genetics) |
| 2 | Breast Neoplasms (genetics) |
| 2 | Combined Modality Therapy |
| 2 | Disease-Free Survival |
| 2 | Genes, BRCA1 |
| 2 | Genes, BRCA2 |
| 2 | Genetic Predisposition to Disease |
| 2 | Maintenance Chemotherapy |
| 2 | Ovarian Neoplasms (pathology) |
| 2 | Prognosis |
| 2 | Risk |
| 1 | Access to Information |
| 1 | Alleles |
| 1 | Antineoplastic Combined Chemotherapy Protocols (adverse effects) |
| 1 | Antineoplastic Combined Chemotherapy Protocols (therapeutic use) |
| 1 | Asian Continental Ancestry Group (genetics) |
| 1 | Ataxia Telangiectasia Mutated Proteins (genetics) |
| 1 | BRCA2 Protein (genetics) |
| 1 | Breast Neoplasms (enzymology) |
| 1 | Breast Neoplasms (epidemiology) |
| 1 | Breast Neoplasms (metabolism) |
| 1 | Carboplatin (administration & dosage) |
| 1 | Carboplatin (adverse effects) |
| 1 | Case-Control Studies |
| 1 | Checkpoint Kinase 2 (genetics) |
| 1 | Consensus |
| 1 | Disclosure (ethics) |
| 1 | Double-Blind Method |
| 1 | Doxorubicin (administration & dosage) |
| 1 | Doxorubicin (adverse effects) |
| 1 | Doxorubicin (analogs & derivatives) |
| 1 | European Continental Ancestry Group (genetics) |
| 1 | Fallopian Tube Neoplasms (drug therapy) |
| 1 | Fallopian Tube Neoplasms (genetics) |
| 1 | Genes, Reporter |
| 1 | Genetic Association Studies |
| 1 | Genome-Wide Association Study |
| 1 | Genome-Wide Association Study (methods) |
| 1 | Genotype |
| 1 | Germ-Line Mutation |
| 1 | Heterozygote |
| 1 | Informed Consent |
| 1 | Male |
| 1 | Medical Oncology |
| 1 | Neoplasm Recurrence, Local (drug therapy) |
| 1 | Neoplasm Recurrence, Local (surgery) |
| 1 | Neoplasms, Glandular and Epithelial (drug therapy) |
| 1 | Neoplasms, Glandular and Epithelial (enzymology) |
| 1 | Nuclear Proteins (genetics) |
| 1 | Ovarian Neoplasms (classification) |
| 1 | Ovarian Neoplasms (diagnosis) |
| 1 | Ovarian Neoplasms (enzymology) |
| 1 | Ovarian Neoplasms (epidemiology) |
| 1 | Ovarian Neoplasms (metabolism) |
| 1 | Ovarian Neoplasms (surgery) |
| 1 | Ovarian Neoplasms (therapy) |
| 1 | Paclitaxel (administration & dosage) |
| 1 | Paclitaxel (adverse effects) |
| 1 | Patient Preference |
| 1 | Peritoneal Neoplasms (drug therapy) |
| 1 | Peritoneal Neoplasms (genetics) |
| 1 | Phthalazines (therapeutic use) |
| 1 | Piperazines (therapeutic use) |
| 1 | Polyethylene Glycols (administration & dosage) |
| 1 | Polyethylene Glycols (adverse effects) |
| 1 | Polymorphism, Single Nucleotide |
| 1 | Practice Guidelines as Topic |
| 1 | Prostatic Neoplasms (epidemiology) |
| 1 | Prostatic Neoplasms (genetics) |
| 1 | Prostatic Neoplasms (metabolism) |
| 1 | Proto-Oncogene Proteins p21(ras) (genetics) |
| 1 | Pyrimidines (therapeutic use) |
| 1 | Quantitative Trait Loci |
| 1 | Societies, Medical |
| 1 | Sulfonamides (therapeutic use) |
| 1 | Survival Rate |
| 1 | Tablets |
| 1 | Tumor Suppressor Proteins (genetics) |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Philipp Harter"
HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i \
-Sk "Philipp Harter" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Allemagne
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Philipp Harter
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
